TERIAK, the pharmaceutical subsidiary of Groupe Kilani, has been awarded the international MSI 20000® (Market Standard Indicator) certification, a distinguished recognition dedicated to evaluating the quality of corporate financial standing.
The certification, conferred by COFICERT—an international certification body operating under the aegis of IGSF, follows a rigorous audit based on financial statements approved by the company’s statutory auditors. The assessment evaluates institutions along two fundamental dimensions: financial strength and performance.
The official presentation ceremony took place on June 25, 2026, at the Euronext headquarters in Paris, during an international gathering that brought together certified companies from more than twenty countries.
This distinction reflects Groupe Kilani’s ongoing commitment to management excellence and financial robustness as cornerstones for the development of all its subsidiaries.
As Tunisia’s leading pharmaceutical industry player, TERIAK employs 650 professionals across two production sites and manufactures over 30 million boxes annually for both the Tunisian market and export.
With a portfolio of more than 600 Marketing Authorizations (MA) in Tunisia and internationally, TERIAK combines licensed manufacturing with generic drug development, serving to expand access to medicines in local and export markets.
